EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1

EXELIXIS, INC.

Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026

$62.68+0.45 (+0.72%)

Close on Oct 19, 2026

Market cap: $16.28B
P/E (TTM): 19.7
Dividend yield: –

Dividends

Exelixis has not reported a dividend

No dividend per share appears in Exelixis's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in Exelixis's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EXEL.

Revenue growth9.2% · median 27.7%

Gross margin96.5% · median 97.9%

Operating margin39.9% · median -19.3%

Net margin35.3% · median -22.5%

Company	Revenue	Growth
NBIX	$3.37B	+34.4%
EXEL	$2.44B	+9.2%
MRNA	$2.23B	-27.6%
BCRX	$940.61M	+68.7%
IMCR	$430.78M	+21.0%
BNTX	–	–

Company

Next earnings (est.): Nov 3, 2026, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: January 1
Employees: 1,077
Held by institutions: 100.0%
Auditor: Ernst & Young LLP
SEC CIK: 939767

Advertisement
300 × 250